The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis
Author
Abstract
Suggested Citation
DOI: 10.1016/j.healthpol.2024.105064
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2005.
"The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s,"
Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 269-292, March.
- Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2003. "The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s," NBER Working Papers 9874, National Bureau of Economic Research, Inc.
- Spicer, Oliver & Grootendorst, Paul, 2022. "The effect of patented drug price on the share of new medicines across OECD countries," Health Policy, Elsevier, vol. 126(8), pages 795-801.
- Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2016.
"Patents and the Global Diffusion of New Drugs,"
American Economic Review, American Economic Association, vol. 106(1), pages 136-164, January.
- Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2014. "Patents and the Global Diffusion of New Drugs," NBER Working Papers 20492, National Bureau of Economic Research, Inc.
- Cockburn, Iain & Lanjouw, Jean O. & Schankerman, Mark, 2016. "Patents and the global diffusion of new drugs," LSE Research Online Documents on Economics 65415, London School of Economics and Political Science, LSE Library.
- Cockburn, Iain & Lanjouw, Jean O. & Schankerman, Mark, 2014. "Patents and the global diffusion of new drugs," LSE Research Online Documents on Economics 60450, London School of Economics and Political Science, LSE Library.
- Iain Cockburn & Jean O. Lanjouw & Mark Schankerman, 2014. "Patents and the Global Diffusion of New Drugs," CEP Discussion Papers dp1298, Centre for Economic Performance, LSE.
- Schankerman, Mark & Cockburn, Iain M & Lanjouw, Jean, 2014. "Patents and the Global Diffusion of New Drugs," CEPR Discussion Papers 10149, C.E.P.R. Discussion Papers.
- Patricia M. Danzon & Andrew J. Epstein, 2012.
"Effects of Regulation on Drug Launch and Pricing in Interdependent Markets,"
Advances in Health Economics and Health Services Research, in: The Economics of Medical Technology, pages 35-71,
Emerald Group Publishing Limited.
- Patricia M. Danzon & Andrew J. Epstein, 2008. "Effects of Regulation on Drug Launch and Pricing in Interdependent Markets," NBER Working Papers 14041, National Bureau of Economic Research, Inc.
- Morgan, Steven G. & Vogler, Sabine & Wagner, Anita K., 2017. "Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia," Health Policy, Elsevier, vol. 121(4), pages 354-362.
- Margaret K. Kyle, 2007. "Pharmaceutical Price Controls and Entry Strategies," The Review of Economics and Statistics, MIT Press, vol. 89(1), pages 88-99, February.
- Lexchin, Joel, 2023. "Therapeutic value of new medicines not submitted to Health Canada 2014-2021: Cross-sectional study," Health Policy, Elsevier, vol. 136(C).
- Nebibe Varol & Joan Costa-Font & Alistair McGuire, 2012. "Does Adoption of Pharmaceutical Innovation Respond to Changes in the Regulatory Environment?," Applied Economic Perspectives and Policy, Agricultural and Applied Economics Association, vol. 34(3), pages 531-553.
- Panos Kanavos & Anna-Maria Fontrier & Jennifer Gill & Olina Efthymiadou, 2020. "Does external reference pricing deliver what it promises? Evidence on its impact at national level," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 129-151, February.
- Nebibe Varol & Joan Costa-Font & Alistair McGuire, 2012. "Does Adoption of Pharmaceutical Innovation Respond to Changes in the Regulatory Environment?," Applied Economic Perspectives and Policy, Agricultural and Applied Economics Association, vol. 34(3), pages 531-553.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Dai, Rong & Watal, Jayashree, 2021. "Product patents and access to innovative medicines," Social Science & Medicine, Elsevier, vol. 291(C).
- Watal, Jayashree & Dai, Rong, 2019. "Product patents and access to innovative medicines in a post-trips-era," WTO Staff Working Papers ERSD-2019-05, World Trade Organization (WTO), Economic Research and Statistics Division.
- Nicolas Houy & Izabela Jelovac, 2014.
"Drug approval decision times, international reference pricing and strategic launches of new drugs,"
Working Papers
halshs-01072741, HAL.
- Izabela Jelovac, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01178631, HAL.
- Nicolas Houy & Izabela Jelovac, 2014. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Working Papers 1425, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
- Izabela Jelovac, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01178636, HAL.
- Izabela Jelovac & Nicolas Houy, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01261578, HAL.
- Izabela Jelovac, 2014. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01138229, HAL.
- Izabela Jelovac, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01178630, HAL.
- Izabela Jelovac & Nicolas Houy, 2017. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01657274, HAL.
- Nicolas Houy & Izabela Jelovac, 2015.
"Drug Launch Timing and International Reference Pricing,"
Health Economics, John Wiley & Sons, Ltd., vol. 24(8), pages 978-989, August.
- Nicolas Houy & Izabela Jelovac, 2013. "Drug launch timing and international reference pricing," Working Papers halshs-00782179, HAL.
- Nicolas Houy & Izabela Jelovac, 2013. "Drug launch timing and international reference pricing," Post-Print halshs-00955848, HAL.
- Nicolas Houy & Izabela Jelovac, 2015. "Drug launch timing and international reference pricing," Post-Print halshs-00993816, HAL.
- Nicolas Houy & Izabela Jelovac, 2013. "Drug launch timing and international reference pricing," Working Papers 1301, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
- Nicolas Houy & Izabela Jelovac, 2013. "Drug launch timing and international reference pricing," Post-Print halshs-00861222, HAL.
- Izabela Jelovac & Nicolas Houy, 2014. "Drug launch timing and international reference pricing," Post-Print halshs-01088164, HAL.
- Nicolas Houy & Izabela Jelovac, 2014. "Drug launch timing and international reference pricing," Post-Print halshs-01096276, HAL.
- Spicer, Oliver & Grootendorst, Paul, 2022. "The effect of patented drug price on the share of new medicines across OECD countries," Health Policy, Elsevier, vol. 126(8), pages 795-801.
- Eric W. Bond & Kamal Saggi, 2023.
"Bargaining over Entry with a Compulsory License Deadline: Price Spillovers and Surplus Expansion,"
World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 20, pages 449-480,
World Scientific Publishing Co. Pte. Ltd..
- Eric W. Bond & Kamal Saggi, 2017. "Bargaining over Entry with a Compulsory License Deadline: Price Spillovers and Surplus Expansion," American Economic Journal: Microeconomics, American Economic Association, vol. 9(1), pages 31-62, February.
- Eric W Bond & Kamal Saggi, 2016. "Bargaining over entry with a compulsory license deadline: Price spillovers and surplus expansion," Vanderbilt University Department of Economics Working Papers 16-00009, Vanderbilt University Department of Economics.
- Rosella Levaggi & Michele Moretto & Paolo Pertile, 2017.
"The Dynamics of Pharmaceutical Regulation and R&D Investments,"
Journal of Public Economic Theory, Association for Public Economic Theory, vol. 19(1), pages 121-141, February.
- Rosella Levaggi & Michele Moretto & Paolo Pertile, 2013. "The dynamics of pharmaceutical regulation and R&D investments," Working Papers 13/2013, University of Verona, Department of Economics.
- Margaret K. Kyle, 2019. "The Single Market in Pharmaceuticals," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 55(1), pages 111-135, August.
- Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 90(C).
- Abdulkadir Civan & Michael Maloney, 2017. "Launch Decisions of Pharmaceutical Companies," Journal of Economics and Financial Analysis, Tripal Publishing House, vol. 1(1), pages 35-58.
- Margaret Kyle & Yi Qian, 2014. "Intellectual Property Rights and Access to Innovation: Evidence from TRIPS," NBER Working Papers 20799, National Bureau of Economic Research, Inc.
- Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016.
"Late-stage pharmaceutical R&D and pricing policies under two-stage regulation,"
Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
- Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
- Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Pierre Dubois & Morten Sæthre, 2020.
"On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector,"
Econometrica, Econometric Society, vol. 88(6), pages 2503-2545, November.
- Dubois, Pierre & Sæthre, Morten, 2017. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Discussion Paper Series in Economics 3/2018, Norwegian School of Economics, Department of Economics.
- Pierre Dubois & Morten Sæthre, 2020. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Post-Print hal-03176406, HAL.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," TSE Working Papers 18-883, Toulouse School of Economics (TSE), revised Mar 2020.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," CEPR Discussion Papers 12649, C.E.P.R. Discussion Papers.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011.
"External referencing and pharmaceutical price negotiation,"
Health Economics, John Wiley & Sons, Ltd., vol. 20(6), pages 737-756, June.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2008. "External referencing and pharmaceutical price negotiation," Working Papers 0815, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011. "External referencing and pharmaceutical price negotiation," Post-Print halshs-00303682, HAL.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2010. "External referencing and pharmaceutical price negotiation," Post-Print halshs-00955856, HAL.
- Kurt Brekke & Dag Dalen & Tor Holmås, 2014.
"Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs,"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 937-951, December.
- Brekke, Kurt R. & Dalen, Dag Morten & Holmås, Tor Helge, 2013. "Diffusion of Pharmaceuticals: Cross-Country Evidence of Anti-TNF drugs," Discussion Paper Series in Economics 7/2013, Norwegian School of Economics, Department of Economics.
- Chatterjee, Chirantan & Kubo, Kensuke & Pingali, Viswanath, 2015. "The consumer welfare implications of governmental policies and firm strategy in markets for medicines," Journal of Health Economics, Elsevier, vol. 44(C), pages 255-273.
- Koenig, Pamina & MacGarvie, Megan, 2011.
"Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe,"
Journal of Health Economics, Elsevier, vol. 30(5), pages 950-965.
- Pamina Koenig & Megan Macgarvie, 2011. "Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe," Post-Print halshs-00754522, HAL.
- Pamina Koenig & Megan Macgarvie, 2011. "Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe," PSE-Ecole d'économie de Paris (Postprint) halshs-00754522, HAL.
- Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
More about this item
Keywords
External price referencing; Internal price referencing; External reference countries; Patented Medicine Prices Review Board; Patented medicine; Drug list price;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:144:y:2024:i:c:s0168851024000745. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.